The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia

European Neuropsychopharmacology

Volumn 26, Issue 2, 2016, Pages 208-224

  Watson, David J G ^a   King, Madeleine V ^a   Gyertyán, Istvan ^b   Kiss, Béla ^b   Adham, Nika ^c   Fone, Kevin C F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GEDEON RICHTER LTD   (Hungary)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cariprazine; Dopamine D3; Neonatal phencyclidine; Object recognition; Schizophrenia; Social isolation

Indexed keywords

ARIPIPRAZOLE; CARIPRAZINE; DOPAMINE 3 RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PIPERAZINE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; COGNITION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FUNCTIONAL DISEASE; LATENT PERIOD; LOCOMOTION; MALE; NEGATIVE SYNDROME; NEWBORN; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL ISOLATION; STATE DEPENDENT LEARNING; VISUAL MEMORY; VOCALIZATION; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DEVELOPMENTAL DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; HUMAN RELATION; LEARNING; MEMORY DISORDERS; RECOGNITION;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; ASSOCIATION LEARNING; DEVELOPMENTAL DISABILITIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; INTERPERSONAL RELATIONS; LOCOMOTION; MALE; MEMORY DISORDERS; PHENCYCLIDINE; PIPERAZINES; RATS; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA;

EID: 84958180532     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.12.020     Document Type: Article

References (86)

1. Adham N., Gyertyán I., Kiss B., Idris N., McLean S., Grayson B., Yoshitake T., Kehr J., Neill J. Cariprazine attenuates PCP-induced increases in prefrontal cortical glutamate levels and deficits in cognition and social behaviour. Eur. Neurophsycopharmacol. 2012, 22:S347.
2. 2 receptors. Biorgan. Med. Chem. Lett. 2012, 22:3437-3440.
3. Bianchi M., Fone K.C.F., Azmi N., Heidbreder C.A., Hagan J.J., Marsden C.A. Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus. Eur. J. Neurosci. 2006, 24:2894-2902.
4. Boctor S.Y., Ferguson S.A. Altered adult locomotor activity in rats from phencyclidine treatment on postnatal days 7, 9 and 11, but not repeated ketamine treatment on postnatal day 7. Neurotoxicology 2010, 31:42-54.
5. Brudzynski S.M. Ethotransmission: communication of emotional states through ultrasonic vocalization in rats. Curr. Opin. Neurobiol. 2013, 23:310-317.
6. 3 dopamine receptors. Behav. Brain Res. 2012, 226:511-518.
7. Bubenikova-Valesova V., Horacek J., Vrajova M., Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 2008, 32:1014-1023.
8. Caccia S., Invernizzi R.W., Nobili A., Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther. Clin. Risk Manag. 2013, 9:319-328.
9. Calabrese J.R., Keck P.E., Starace A., Lu K., Ruth A., Laszlovszky I., Nemeth G., Durgam S. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry 2015, 76:284-292.
10. Durgam S., Starace A., Li D., Migliore R., Ruth A., Nemeth G., Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr. Res. 2014, 152:450-457.
11. Durgam S., Starace A., Li D., Migliore R., Ruth A., Nemeth G., Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015, 17:63-75.
12. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav. Brain Res. 1988, 31:47-59.
13. Fabricius K., Helboe L., Fink-Jensen A., Wortwein G., Steiniger-Brach B. Pharmacological characterization of social isolation-induced hyperactivity. Psychopharmacology 2010, 215:257-266.
14. Fabricius K., Helboe L., Fink-Jensen A., Wortwein G., Steiniger-Brach B. Pharmacological characterization of social isolation-induced hyperactivity. Psychopharmacology 2011, 215:257-266.
15. Fone K.C., Shalders K., Fox Z.D., Arthur R., Marsden C.A. Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology 1996, 123:346-352.
16. Fone K.C.F., Porkess M.V. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2008, 32:1087-1102.
17. Fulford A.J., Marsden C.A. Effect of isolation-rearing on conditioned dopamine release in vivo in the nucleus accumbens of the rat. J. Neurochem. 1998, 70:384-390.
18. Gaskin P.L., Alexander S.P., Fone K.C. Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat. Psychopharmacology 2014, 231:2533-2545.
19. Goosens K.A., Maren S. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn. Mem. 2001, 8:148-155.
20. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72:41-51.
21. 3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs 2010, 11:823-832.
22. 2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int. 2011, 59:925-935.
23. 2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmied. Arch. Pharmacol. 2008, 378:529-539.
24. Hall F.S., Wilkinson L.S., Humby T., Inglis W., Kendall D.A., Marsden C.A., Robbins T.W. Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol. Biochem. Behav. 1998, 59:859-872.
25. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D-receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010, 1187:4-34.
26. Herbener E.S. Impairment in long-term retention of preference conditioning in schizophrenia. Biol. Psychiatry 2009, 65:1086-1090.
27. Howes O., McCutcheon R., Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacology 2015, 29:97-115.
28. Howes S.R., Dalley J.W., Morrison C.H., Robbins T.W., Everitt B.J. Leftward shift in the acquisition of cocaine self-administration in isolation-reared rats: relationship to extracellular levels of dopamine, serotonin and glutamate in the nucleus accumbens and amygdala-striatal FOS expression. Psychopharmacology 2000, 151:55-63.
29. Ingallinesi M., Le Bouil L., Faucon Biguet N., Do Thi A., Mannoury la Cour C., Millan M.J., Ravassard P., Mallet J., Meloni R. Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats. Mol. Psychiatry 2015, 20:951-958.
30. Jones C.A., Brown A.M., Auer D.P., Fone K.C. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology 2011, 214:269-283.
31. Jones C.A., Watson D.J.G., Fone K.C.F. Animal models of schizophrenia. Br. J. Pharmacol. 2011, 164:1162-1194.
32. Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K., Laszlovszky I., Durgam S. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J. Clin. Psychopharmacol. 2015, 35:367-373.
33. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
34. King, M.V., Negm, O., Tighe, P., Knapp, S., Wigmore, P., Fone, K.C.F., 2013. Behavioural, Molecular and Glutamatergic Changes in a Developmental Model of Schizophrenia, and Reversal by a 5-HT6 Receptor Antagonist. 〈〉. http://www.ecnp.eu/~/media/Files/ecnp/meetings/workshops/WS%202013/Posters/King.pdf.
35. King M.V., Seeman P., Marsden C.A., Fone K.C.F. Increased dopamine D-2(High) receptors in rats reared in social isolation. Synapse 2009, 63:476-483.
36. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A., Fone K.C. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47:195-204.
37. 3 receptor occupancy in vivo compared with other antipsychotics. Biol. Psychiatry 2012, 71:40S.
38. Kiss B., Horváth A., Némethy Z., Schmidt E., Laszlovszky I., Bugovics G., Fazekas K., Hornok K., Orosz S., Gyertyán I., Ágai-Csongor E., Domány G., Tihanyi K., Adham N., Szombathelyi Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 2010, 333:328-340.
39. Kucharska-Pietura K., Tylec A., Czernikiewicz A., Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Medical science monitor. Int. Med. J. Exp. Clin. Res. 2012, 18:CR44-CR49.
40. Lapiz M.D., Fulford A., Muchimapura S., Mason R., Parker T., Marsden C.A. Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission. Neurosci. Behav. Physiol. 2003, 33:13-29.
41. Laszy J., Laszlovszky I., Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 2005, 179:567-575.
42. Li S.J., Huang Z.Y., Ye Y.L., Yu Y.P., Zhang W.P., Wei E.Q., Zhang Q. Influence of object material and inter-trial interval on novel object recognition test in mice. Zhejiang da xue xue bao Yi xue Ban. J. Zhejiang Univ. Med. Sci. 2014, 43:346-352.
43. Lim A.L., Taylor D.A., Malone D.T. A two-hit model: behavioural investigation of the effect of combined neonatal MK-801 administration and isolation rearing in the rat. J. Psychopharmacol. 2012, 26:1252-1264.
44. Lyon L., Saksida L.M., Bussey T.J. Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology 2012, 220:647-672.
45. Marsden C.A., King M.V., Fone K.C.F. Influence of social isolation in the rat on serotonergic function and memory-relevance to models of schizophrenia and the role of 5-HT(6) receptors. Neuropharmacology 2011, 61:400-407.
46. McCormack P.L. Cariprazine: first global approval. Drugs 2015, 75:2035-2043.
47. McIntosh A.L., Ballard T.M., Steward L.J., Moran P.M., Fone K.C. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology 2013, 228:31-42.
48. McIntosh A.L., Ballard T.M., Steward L.J., Moran P.M., Fone K.C.F. Clozapine reverses recognition memory but not social interaction deficits in a "dual-hit" rat model of schizophrenia. Schizophr. Res. 2012, 136:S282.
49. Meffre J., Chaumont-Dubel S., la Cour C.M., Loiseau F., Watson D.J.G., Dekeyne A., Seveno M., Rivet J.-M., Gaven F., Deleris P., Herve D., Fone K.C.F., Bockaert J., Millan M.J., Marin P. 5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO. Mol. Med. 2012, 4:1043-1056.
50. Millan M.J., Brocco M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3)>D(2) antagonist, S33138. Therapie 2008, 63:187-229.
51. Millan M.J., Fone K., Steckler T., Horan W.P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2014, 24:645-692.
52. 2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exp. Ther. 2008, 324:1212-1226.
53. Mintz J., Kopelowicz A. CUtLASS confirms CATIE. Arch. Gen. Psychiatry 2007, 64:978. 978.
54. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17:1206-1227.
55. Moller M., Du Preez J.L., Emsley R., Harvey B.H. Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2011, 21:471-483.
56. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 2007, 51:173-184.
57. Mu P., Fuchs T., Saal D.B., Sorg B.A., Dong Y., Panksepp J. Repeated cocaine exposure induces sensitization of ultrasonic vocalization in rats. Neurosci. Lett. 2009, 453:31-35.
58. Nagai T., Murai R., Matsui K., Kamei H., Noda Y., Furukawa H., Nabeshima T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 2009, 202:315-328.
59. Neill J.C., Grayson B., Kiss B., Gyertyan I., Ferguson P., Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur. J. Neuropsychopharmacol. 2015, 10.1016/j.euroneuro.2015.11.016.
60. Okada R., Fujiwara H., Mizuki D., Araki R., Yabe T., Matsumoto K. Involvement of dopaminergic and cholinergic systems in social isolation-induced deficits in social affiliation and conditional fear memory in mice. Neuroscience 2015, 299:134-145.
61. Papp M., Gruca P., Lason-Tyburkiewicz M., Adham N., Kiss B., Gyertyan I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav. Pharmacol. 2014, 25:567-574.
62. Pelletier M., Achim A.M., Montoya A., Lal S., Lepage M. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 74:233-252.
63. Pitsikas N., Rigamonti A.E., Cella S.G., Muller E.E. The 5-HT 1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Res. 2003, 983:215-222.
64. Rajagopal L., Massey B.W., Huang M., Oyamada Y., Meltzer H.Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr. Pharm. Des. 2014, 20:5104-5114.
65. Richmond M.A., Yee B.K., Pouzet B., Veenman L., Rawlins J.N., Feldon J., Bannerman D.M. Dissociating context and space within the hippocampus: effects of complete, dorsal, and ventral excitotoxic hippocampal lesions on conditioned freezing and spatial learning. Behav. Neurosci. 1999, 113:1189-1203.
66. Sachs G.S., Greenberg W.M., Starace A., Lu K., Ruth A., Laszlovszky I., Nemeth G., Durgam S. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J. Affect. Disord. 2015, 174:296-302.
67. Sadananda M., Natusch C., Karrenbauer B., Schwarting R.K. 50-kHz calls in rats: effects of MDMA and the 5-HT(1A) receptor agonist 8-OH-DPAT. Pharmacol. Biochem. Behav. 2012, 101:258-264.
68. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10:59-90.
69. Seffer D., Rippberger H., Schwarting R.K., Wohr M. Pro-social 50-kHz ultrasonic communication in rats: post-weaning but not post-adolescent social isolation leads to social impairments-phenotypic rescue by re-socialization. Front. Behav. Neurosci. 2015, 9:102.
70. Seneca N., Finnema S.J., Laszlovszky I., Kiss B., Horváth A., Pásztor G., Kapas M., Gyertyán I., Farkas S., Innis R.B., Halldin C., Gulyas B. Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology 2011, 218:579-587.
71. Shohamy D., Mihalakos P., Chin R., Thomas B., Wagner A.D., Tamminga C. Learning and generalization in schizophrenia: effects of disease and antipsychotic drug treatment. Biol. Psychiatry 2010, 67:926-932.
72. Simola N., Fenu S., Costa G., Pinna A., Plumitallo A., Morelli M. Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. Neuropharmacology 2012, 63:224-234.
73. Simola N., Ma S.T., Schallert T. Influence of acute caffeine on 50-kHz ultrasonic vocalizations in male adult rats and relevance to caffeine-mediated psychopharmacological effects. Int. J. Neuropsychopharmacol. 2010, 13:123-132.
74. 2 receptor occupancy in patients with schizophrenia: s clinical PET study with [11C]-(+)-PHNO. Neuropharmacology 2013, 38:W128.
75. Snigdha S., Thumbi C., Reynolds G.P., Neill J.C. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J. Psychopharmacology 2008, 22:567-571.
76. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug. Targets 2006, 5:25-43.
77. 3 receptors. Eur. J. Pharmacol. 2011, 668:355-365.
78. Van Den Berg C.L., Van Ree J.M., Spruijt B.M. Sequential analysis of juvenile isolation-induced decreased social behavior in the adult rat. Physiol. Behav. 1999, 67:483-488.
79. 2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 2012, 37:770-786.
80. Watson D.J., Marsden C.A., Millan M.J., Fone K.C. Blockade of dopamine D(3) but not D(2) receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol. 2012, 15:471-484.
81. Wilson C.A., Koenig J.I. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2014, 24:759-773.
82. Wintink A.J., Brudzynski S.M. The related roles of dopamine and glutamate in the initiation of 50-kHz ultrasonic calls in adult rats. Pharmacol. Biochem. Behav. 2001, 70:317-323.
83. Wongwitdecha N., Marsden C.A. Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Behav. Brain Res. 1996, 75:27-32.
84. Woods S., Clarke N.N., Layfield R., Fone K.C. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 2012, 167:436-449.
85. Young J.W., Geyer M.A. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J. Psychopharmacology 2015, 29:178-196.
86. Zimnisky R., Chang G., Gyertyán I., Kiss B., Adham N., Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology 2013, 226:91-100.